Xylonix and LysinBio to Combat Potential Disease X of Bacterial Origin

Xylonix and LysinBio Partner to Combat Potential Disease X of Bacterial Origin

“...to focus beyond viruses - readying for deadlier bacterial Disease X with super antibacterials and nasal sprays.”

 

Singapore and Daejeon, South Korea – 18 November 2024  

Xylonix PTE. LTD. and LysinBio Co. Ltd. announced a co-development partnership aimed at addressing the escalating concern of Disease X, specifically of deadlier bacterial origins. This collaboration represents the first significant initiative to tackle the potential threat of Disease X caused by antibiotic-resistant bacteria, a concern that has been largely overshadowed by viral threats (read:  “Why Bacterial Disease X is More Deadly Than Viral). 

 

Disease X: A New Perspective on Global Health Threats 

While the global health community has been vigilant about the threat of viral pandemics, the potential for Disease X of bacterial origin has not been adequately addressed. Adopted in 2018 by the World Health Organization (WHO), Disease X refers to a hypothetical, unknown pathogen that could cause a future epidemic or pandemic. The recent surge in deaths caused by the air-transmissible Streptococcus A (Strep A) in Japan underscores the devastating impact that bacterial infections can have, with sepsis leading to fatalities in as little as 48 hours and a fatality rate of 30%. 

 

Innovative Solutions for a Critical Challenge 

Under this agreement, Xylonix and LysinBio will co-develop innovative products to combat antibiotic-resistant bacteria, leveraging LysinBio’s proprietary engineered endolysins. These endolysins represent a significant advancement by being effective against both Gram-negative and Gram-positive bacteria. The collaboration will bring to market several key products, including resistance-fighting medical disinfectants for surgical facilities, surgical consumables, and eventually, antibacterial cocktails for treating deadly infections from super bacteria. 

 

Commitment to Rapid Solutions for Global Health Threats 

Since the COVID-19 pandemic, there has been an alarming rise in bacterial infectious diseases and deaths from sepsis. This partnership aims to address these growing threats by rapidly developing and bringing to market effective solutions to control antibiotic-resistant bacteria in medical environments. Xylonix, the originator of these innovative product ideas, will lead the product development and marketing efforts, while LysinBio will leverage its expertise in endolysin-related technologies. LysinBio recently established the endolysin product scaling via domestic licensing of its agricultural use in Korea.  

 

“With the increasing threat of antibiotic-resistant bacteria, commonly known as superbugs, it is crucial to expand our focus beyond viral pathogens and address the potential for a Disease X of bacterial origin,” said Jinhyuk Chung, CEO of Xylonix. “Our partnership with LysinBio represents a significant step forward in developing effective solutions to combat these emerging threats.” 

 

About Xylonix PTE. LTD. 

Singapore-based pharma Xylonix focuses on products and developments that comprehensively address post-COVID immune dysfunction, including pharmaceuticals and consumer goods combating turbo cancers, autoimmune disorders, and airborne infectious diseases. With a commitment for timely solutions for present health challenges, Xylonix is actively expanding the availability of its products to clinics across Singapore, Korea, and abroad with its antibacterial and antiviral nasal spray as the leading product for infectious diseases and rhinitis. It is also developing C10-LIPO, a first-in-class immunotherapeutic drug for normalization of dysfunctional macrophages for potential applications against highly metastatic cancers and autoimmune disorders with high serum IL6 such as long COVID.  

 

About LysinBio Co. Ltd. 

LysinBio, based in Daejeon, South Korea, is pioneering the development of resistance-cutting biological antibacterial agents, offering robust solutions to combat deadly super bacteria such as MRSA using engineered bacteriophage functions. Utilizing its proprietary eLBP (engineered live biotherapeutic products) platform, LysinBio addresses both human and industrial needs. Additionally, the company is advancing protein drug delivery with innovative platform technology that enhances the efficacy and targeted delivery of protein drugs. 

 

For Media Inquiries, Please Contact: 

 

Media Officer: Gregory Irving – g.irving@xylonix.io